New pill targets Hard-to-Treat cancers with MAPK mutations
NCT ID NCT05886920
First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This early-phase study tests a new oral drug, D3S-002, in adults with advanced solid tumors that have MAPK pathway mutations and have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can control tumor growth. About 67 participants will receive the drug alone or with another therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS WITH MAPK PATHWAY MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
D3 Bio Investigative Site
Detroit, Michigan, 48202, United States
-
D3 Bio Investigative Site
New York, New York, 10029, United States
-
D3 Bio Investigative Site
Blacktown, New South Wales, 2148, Australia
-
D3 Bio Investigative Site
Bedford Park, South Australia, 5042, Australia
-
D3 Bio Investigative Site
Nedlands, Western Australia, 6009, Australia
-
D3 Bio Investigative Site
Beijing, Beijing Municipality, 100142, China
-
D3 Bio Investigative Site
Guangzhou, Guangdong, 510080, China
-
D3 Bio Investigative Site
Harbin, Heilong Jiang, 150081, China
-
D3 Bio Investigative Site
Shanghai, Shanghai Municipality, 201801, China
-
D3 Bio Investigative Site
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.